Management of cutaneous adverse events associated with daclizumab treatment in multiple sclerosis patients

Daclizumab high-yield process (DAC HYP) has recently been identified as an effective targeted therapy treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Its use in investigations has also led to breakthroughs in understanding the underlying pathogenesis of MS and in the development of novel therapeutic strategies. However, cutaneous adverse events (AEs) are not uncommon occurrences, as observed in recent clinical trials of DAC HYP treatment in RRMS patients. While these cutaneous AEs are not life-threatening, skin reactions can affect patient quality of life and lead to treatment interruption or discontinuation, resulting in suboptimal therapeutic outcomes. Currently, there are no specific guidelines for the prevention and management of cutaneous sequelae in DAC HYP therapy. There is a need to advocate for dermatologic supportive care in the multidisciplinary management of MS patients. We have established an evaluation and management algorithm to maximise patient treatment outcomes and quality of life through early recognition of and intervention against cutaneous AEs associated with daclizumab treatment.

Mr Jacson Shen